Results from Phase 2 IgAN trials support the potential benefits of dual inhibition of BAFF and APRIL in IgAN, and ongoing Phase 3 clinical studies will shed light on how this approach may offer greater and/or more sustained efficacy in preserving kidney function and preventing kidney failure in patients with IgAN. This evidence concerns the gene TNFSF13 and kidney failure.